

## Table 97TVC - Cervarix, August 11, 2009

- Table 97TVC Summary table of vaccine efficacy against virological endpoints associated with specific oncogenic HPV types (by PCR) in HPV DNA negative subjects using conditional exact method (TVC irrespective of baseline)

TVC irrespective of baseline										
Event Type	6-month persistent infection					12-month persistent infection				
	n*	%	LL	UL	P-value	n*	%	LL	UL	P-value
HPV-31	223/398	44.3	33.6	53.3	<0.0001	135/219	38.5	22.5	51.3	<0.0001
HPV-33	159/216	26.3	8.2	41.0	0.0034	80/108	25.8	-1.5	46.0	0.0475
HPV-35	117/96	-22.4	-64.5	8.6	0.1484	58/43	-35.4	-110.3	12.1	0.1355
HPV-45	69/158	56.4	40.9	68.1	<0.0001	40/63	36.4	1.9	59.2	0.0292
HPV-51	582/660	12.1	1.0	21.9	0.0234	245/302	19.0	2.9	32.4	0.0149
HPV-58	248/244	-2.0	-23.4	15.7	0.8550	127/106	-20.4	-59.6	8.9	0.1663
HPV-68	256/259	0.9	-19.4	17.7	0.9287	104/107	2.5	-30.8	27.3	0.8899

\* n=number of subjects reporting at least one event in each group (HPV group/HAV group).

Note: Similar list of oncogenic HPV types of Table 97 (page 355) of the Clinical report have been retained.

For all subjects, follow-up period starts at first visit

For 12 Month persistent, subjects have at least 10 months of follow-up after first visit

For 6 Month persistent, subjects have at least 5 months of follow-up after first visit

VE (%) = Vaccine Efficacy (Conditional Method)

LL, UL = 96.1% Lower and Upper confidence limits, P-value = Two-sided Fisher Exact test